Minimization of masking in signal detection from Chinese spontaneous reporting databases based on data removal strategy

This study aimed to develop an experimental method for minimizing masking in signal detection using a data removal strategy. Reports in the Chinese Spontaneous Reporting Database (CSRD) between 2010 and 2011 were selected as the initial database. A reference database including known signals was used for performance evaluation. The data removal strategy was as follows: 1) the data were sorted according to the frequency of drug–event combinations (DECs), and the top n% of DECs was removed from the initial database; 2) signals of disproportionate reporting were detected using the MHRA for each new database; and 3) the performance was evaluated based on the reference database before and after data removal. The five adverse events (AEs) of interest: renal failure acute, skin exfoliation, syncope, leucopenia, and tetany were selected to test the result. Our experimental results showed that the value of F index increased first and then decreased with data removal, and the value of benefit rate (BR) rose in the new database constantly. In the sixth experiment, the F index reached a peak value (50.63%), and the performance of unmasking achieved the best, where the value of BR was changed from 10.72% to 52.12% and the number of known signals exposed was changed from 6314 to 6787. The performance of unmasking achieved the best when the top 6% of DECs were removed from the CSRD.

[1]  Lehana Thabane,et al.  Application of data mining techniques in pharmacovigilance. , 2003, British journal of clinical pharmacology.

[2]  Ismaïl Ahmed,et al.  A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases , 2016, Drug Safety.

[3]  M. Lapeyre-Mestre,et al.  Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. , 2006, Joint, bone, spine : revue du rhumatisme.

[4]  A. Bate,et al.  Quantitative signal detection using spontaneous ADR reporting , 2009, Pharmacoepidemiology and drug safety.

[5]  S. Evans,et al.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.

[6]  P. Waller,et al.  Regulatory Pharmacovigilance in the United Kingdom: Current Principles and Practice , 1996, Pharmacoepidemiology and drug safety.

[7]  Richard Beasley,et al.  Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. , 2004, Clinical therapeutics.

[8]  Andrew Bate,et al.  Bayesian Confidence Propagation Neural Network , 2007, Drug safety.

[9]  A. Bate,et al.  A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.

[10]  Kenneth J Rothman,et al.  The reporting odds ratio and its advantages over the proportional reporting ratio , 2004, Pharmacoepidemiology and drug safety.

[11]  Francesco Salvo,et al.  Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase® , 2016, Drug Safety.

[12]  Frantz Thiessard,et al.  The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions , 2005, Pharmacoepidemiology and drug safety.

[13]  Manfred Hauben,et al.  An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database , 2010, Drug safety.

[14]  E. Puijenbroek,et al.  Application of Quantitative Signal Detection in the Dutch Spontaneous Reporting System for Adverse Drug Reactions , 2003, Drug safety.

[15]  William DuMouchel,et al.  Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .

[16]  M. Lindquist,et al.  A Data Mining Approach for Signal Detection and Analysis , 2002, Drug safety.

[17]  F. Haramburu,et al.  Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. , 2003, British journal of clinical pharmacology.